-
1
-
-
84956767541
-
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
-
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
-
(2016)
Arthritis Rheumatol
, vol.68
, Issue.1
, pp. 1-26
-
-
Singh, J.A.1
Saag, K.G.2
Bridges, S.L.3
Akl, E.A.4
Bannuru, R.R.5
Sullivan, M.C.6
-
2
-
-
85019702082
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
-
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77.
-
(2017)
Ann Rheum Dis
, vol.76
, Issue.6
, pp. 960-977
-
-
Smolen, J.S.1
Landewé, R.2
Bijlsma, J.3
Burmester, G.4
Chatzidionysiou, K.5
Dougados, M.6
-
3
-
-
84930323836
-
Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis
-
Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm. 2015;21(5):409-23.
-
(2015)
J Manag Care Spec Pharm
, vol.21
, Issue.5
, pp. 409-423
-
-
Buckley, F.1
Finckh, A.2
Huizinga, T.W.3
Dejonckheere, F.4
Jansen, J.P.5
-
4
-
-
85006699538
-
Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database
-
Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm. 2016;22(12):1457-71.
-
(2016)
J Manag Care Spec Pharm
, vol.22
, Issue.12
, pp. 1457-1471
-
-
Harnett, J.1
Gerber, R.2
Gruben, D.3
Koenig, A.S.4
Chen, C.5
-
5
-
-
84908370285
-
Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis
-
Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675-84.
-
(2014)
Arthritis Rheumatol
, vol.66
, Issue.10
, pp. 2675-2684
-
-
Winthrop, K.L.1
Yamanaka, H.2
Valdez, H.3
Mortensen, E.4
Chew, R.5
Krishnaswami, S.6
-
6
-
-
84924842188
-
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
-
Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872-85.
-
(2014)
Rheumatology (Oxford)
, vol.53
, Issue.10
, pp. 1872-1885
-
-
Souto, A.1
Maneiro, J.R.2
Salgado, E.3
Carmona, L.4
Gomez-Reino, J.J.5
-
7
-
-
84965060726
-
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
-
Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843-7.
-
(2016)
Ann Rheum Dis
, vol.75
, Issue.10
, pp. 1843-1847
-
-
Curtis, J.R.1
Xie, F.2
Yun, H.3
Bernatsky, S.4
Winthrop, K.L.5
-
8
-
-
85029457249
-
Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
-
Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033-9.
-
(2017)
Pharmacoepidemiol Drug Saf
, vol.26
, Issue.9
, pp. 1033-1039
-
-
Berger, M.L.1
Sox, H.2
Willke, R.J.3
Brixner, D.L.4
Eichler, H.G.5
Goettsch, W.6
-
9
-
-
84858645799
-
Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report
-
Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand SL. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012;15(2):217-30.
-
(2012)
Value Health
, vol.15
, Issue.2
, pp. 217-230
-
-
Berger, M.L.1
Dreyer, N.2
Anderson, F.3
Towse, A.4
Sedrakyan, A.5
Normand, S.L.6
-
10
-
-
78751479768
-
Claims data analysis of dosing and cost of TNF antagonists
-
Gu NY, Huang XY, Fox KM, Patel VD, Baumgartner SW, Chiou CF. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits. 2010;2:351-9.
-
(2010)
Am J Pharm Benefits
, vol.2
, pp. 351-359
-
-
Gu, N.Y.1
Huang, X.Y.2
Fox, K.M.3
Patel, V.D.4
Baumgartner, S.W.5
Chiou, C.F.6
-
11
-
-
77958121473
-
Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database
-
Petri H, Maldonato D, Robinson NJ. Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. BMC Musculoskelet Disord. 2010;11:247.
-
(2010)
BMC Musculoskelet Disord
, vol.11
, pp. 247
-
-
Petri, H.1
Maldonato, D.2
Robinson, N.J.3
-
12
-
-
84904791286
-
Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims
-
Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014;36(7):996-1004.
-
(2014)
Clin Ther
, vol.36
, Issue.7
, pp. 996-1004
-
-
Curtis, J.R.1
Schabert, V.F.2
Harrison, D.J.3
Yeaw, J.4
Korn, J.R.5
Quach, C.6
-
13
-
-
84957577298
-
Effectiveness and costs of biologics in veterans with rheumatoid arthritis
-
Sauer BC, Teng CC, He T, Leng J, Lu CC, Curtis JR, Cannon GW. Effectiveness and costs of biologics in veterans with rheumatoid arthritis. Am J Pharm Benefits. 2015;7(6):280-9.
-
(2015)
Am J Pharm Benefits
, vol.7
, Issue.6
, pp. 280-289
-
-
Sauer, B.C.1
Teng, C.C.2
He, T.3
Leng, J.4
Lu, C.C.5
Curtis, J.R.6
Cannon, G.W.7
-
14
-
-
84929078493
-
Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis
-
Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. J Med Econ. 2015;18(5):376-89.
-
(2015)
J Med Econ
, vol.18
, Issue.5
, pp. 376-389
-
-
Bonafede, M.1
Johnson, B.H.2
Princic, N.3
Shah, N.4
Harrison, D.J.5
-
15
-
-
80053174347
-
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis
-
Curtis JR, Baddley JW, Yang S, Patkar N, Chen L, Delzell E, et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):R155.
-
(2011)
Arthritis Res Ther
, vol.13
, Issue.5
, pp. R155
-
-
Curtis, J.R.1
Baddley, J.W.2
Yang, S.3
Patkar, N.4
Chen, L.5
Delzell, E.6
-
20
-
-
84929087628
-
-
Princeton, NJ: Bristol-Myers Squibb Company.
-
Bristol-Myers Squibb Company. Orencia (abatacept) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
-
(2014)
Orencia (abatacept) prescribing information
-
-
-
21
-
-
0004879274
-
-
Malvern, PA: Centocor Ortho Biotech, Inc.
-
Centocor Ortho Biotech, Inc. Remicade (infliximab) prescribing information. Malvern, PA: Centocor Ortho Biotech, Inc.; 2013.
-
(2013)
Remicade (infliximab) prescribing information
-
-
-
22
-
-
85013878103
-
-
South San Francisco, CA: Biogen/Genentech USA, Inc.
-
Biogen/Genentech USA, Inc. Rituxan (rituximab) prescribing information. South San Francisco, CA: Biogen/Genentech USA, Inc.; 2016.
-
(2016)
Rituxan (rituximab) prescribing information
-
-
-
24
-
-
34848839939
-
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies
-
Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896-904.
-
(2007)
Arthritis Rheum
, vol.56
, Issue.9
, pp. 2896-2904
-
-
Dixon, W.G.1
Symmons, D.P.2
Lunt, M.3
Watson, K.D.4
Hyrich, K.L.5
-
25
-
-
84903483215
-
Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis
-
Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(7):990-7.
-
(2014)
Arthritis Care Res (Hoboken)
, vol.66
, Issue.7
, pp. 990-997
-
-
Curtis, J.R.1
Yang, S.2
Patkar, N.M.3
Chen, L.4
Singh, J.A.5
Cannon, G.W.6
-
26
-
-
85006819043
-
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis
-
Kawashima H, Kagami SI, Kashiwakuma D, Takahashi K, Yokota M, Furuta S, et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int. 2017;37(3):369-76.
-
(2017)
Rheumatol Int
, vol.37
, Issue.3
, pp. 369-376
-
-
Kawashima, H.1
Kagami, S.I.2
Kashiwakuma, D.3
Takahashi, K.4
Yokota, M.5
Furuta, S.6
-
27
-
-
84904818200
-
The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy
-
Kissin EY. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy. Clin Ther. 2014;36(7):1114-6.
-
(2014)
Clin Ther
, vol.36
, Issue.7
, pp. 1114-1116
-
-
Kissin, E.Y.1
-
28
-
-
79959790816
-
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
-
Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70(8):1401-6.
-
(2011)
Ann Rheum Dis
, vol.70
, Issue.8
, pp. 1401-1406
-
-
Curtis, J.R.1
Xie, F.2
Chen, L.3
Baddley, J.W.4
Beukelman, T.5
Saag, K.G.6
|